LV Diastolic Function and HFpEF Calculator (ASE 2025, ESC 2026)

This calculator follows the ASE 2025 diastolic function algorithm. It first decides whether diastolic dysfunction is present, then estimates left atrial pressure (LAP) and assigns a grade. A separate module checks the echocardiographic criteria and natriuretic peptide cut-offs for HFpEF from the 2026 ESC heart failure guidelines. We built it for physicians who perform and report adult echocardiograms.

Medical content: Radosław Piątkowski, MD, PhD, DSc, and Monika Budnik, MD, PhD, DSc (Polish degree: dr hab. n. med. i n. o zdr.) · Updated October 2026

How to use

  • Start with rhythm and comorbidities. Atrial fibrillation (AF), moderate or severe mitral annular calcification (MAC), non-cardiac pulmonary hypertension and heart transplant switch the calculator to the dedicated ASE 2025 algorithms.
  • Enter the required measurements: E, A, septal and lateral e′, peak tricuspid regurgitation (TR) velocity. The calculator derives E/A, average e′ and E/e′.
  • If the result calls for additional variables, add LA reservoir strain (LARS), pulmonary vein S/D ratio, LAVi or, alternatively, IVRT. Without them, the calculator lists the supplemental methods you can use.
  • Fill in the HFpEF module separately: LVEF, NT-proBNP or BNP, age, and the ESC 2026 Table 10 criteria. The H2FPEF score is optional.

Two questions: is there diastolic dysfunction, and what is the LA pressure?

ASE 2025 separates two assessments that often blur in daily reporting. Figure 2 (p. 553) asks whether LV diastolic dysfunction is present. Figure 3 (p. 554) asks whether filling pressure is elevated. A patient can have diastolic dysfunction with normal LAP. With reduced e′, normal E/e′ and TR velocity/PASP, and E/A ≤ 0.8, that patient has grade 1.

Figure 2 starts with e′. Reduced e′ plus at least one marker from step 2 confirms dysfunction. With normal e′, you need at least two markers.

StepParameterCut-off
1reduced e′septal ≤ 6 cm/s or lateral ≤ 7 cm/s or average ≤ 6.5 cm/s (age-specific cut-offs optional, Table 6)
2average E/e′> 14
2LA reservoir strain (LARS)≤ 18%
2E/A≤ 0.8 or ≥ 2
2LAVi> 34 mL/m² (after excluding athletes, anaemia, AF/atrial flutter, mitral valve disease)
supportiveLVMI> 95 g/m² in women, > 115 g/m² in men (after excluding athletes)
Table 1. Diagnosis of diastolic dysfunction (ASE 2025, Fig. 2)

Rule: dysfunction is present with reduced e′ and ≥ 1 step-2 marker, or with normal e′ and ≥ 2 markers.

LA pressure and diastolic dysfunction grade (ASE 2025, Fig. 3)

Figure 3 applies to patients in sinus rhythm, regardless of LVEF. Do not use it in moderate or severe MAC, severe primary mitral regurgitation, mitral stenosis of any severity, AF, LVAD, non-cardiac pulmonary hypertension, heart transplant, constrictive pericarditis, or after mitral valve repair, replacement or TEER.

VariableAbnormal when
V1: e′septal ≤ 6 or lateral ≤ 7 or average ≤ 6.5 cm/s (age-specific cut-offs optional, Table 6)
V2: E/e′septal ≥ 15 or lateral ≥ 13 or average ≥ 14
V3: TR / PASPTR ≥ 2.8 m/s or PASP ≥ 35 mmHg (PASP when RAP can be estimated; TR in the absence of parenchymal or vascular lung disease)
Table 2. Three primary variables (Fig. 3)

Figure 3 logic:

  • 0 of 3 abnormal: normal diastolic function, normal LAP.
  • V1 only: E/A ≤ 0.8 means grade 1 with normal LAP (diastolic exercise echo if the patient has symptoms). E/A > 0.8 leads to the additional variables. If none of them is abnormal, ASE 2025 states that LAP is likely normal. The calculator then reports normal LAP and impaired relaxation (reduced e′) without assigning a grade, because ASE 2025 defines grade 1 by E/A ≤ 0.8.
  • V2 only, V3 only, or any 2 of 3: additional variables.
  • 3 of 3: elevated LAP, grade by E/A.
LevelParameterSuggests elevated LAP when
additional variablepulmonary vein S/D≤ 0.67
additional variableLARS≤ 18%
additional variableLAVi> 34 mL/m²
additional variableIVRT (alternative; with normal LVEF, use it to check an S/D ratio > 0.67)≤ 70 ms
supplemental methodend-diastolic pulmonary regurgitation velocity / PADP≥ 2 m/s / ≥ 16 mmHg (no lung disease)
supplemental methodL wave≥ 50 cm/s
LVEDP only (does not count towards LAP)premature termination of mitral inflow before QRS and diastolic mitral regurgitationmay indicate elevated LVEDP (p. 555; after excluding advanced AV block, atrial flutter and organised atrial fibrillation activity; PR > 200 ms can also cause it)
supplemental methodAr−A duration> 30 ms (Fig. 3); the text on p. 555 also describes Ar > 35 cm/s with Ar−A > 30 ms as an early stage with elevated LVEDP and normal mean LAP
supplemental methodValsalva manoeuvreE/A decrease ≥ 50%
Table 3. Additional variables and supplemental methods (Fig. 3)

One or more abnormal additional variables means elevated LAP; none means normal LAP. Use the supplemental methods when the additional variables are unavailable or unreliable; each one is sufficient on its own.

ResultCriterion
normal diastolic functionno abnormal primary variables
grade 1reduced e′, normal E/e′ and PASP, E/A ≤ 0.8 (normal LAP)
grade 2elevated LAP and E/A < 2 (mildly to moderately elevated LAP)
grade 3elevated LAP and E/A ≥ 2 (markedly elevated LAP)
Table 4. Grades (ASE 2025)

Figure 3 has no "indeterminate" category. The calculator returns "LAP cannot be determined" only when data are missing from both the additional variables and the supplemental methods. This is a design decision by Akademia Echokardiografii, not part of the guideline.

What the echo report should include (ASE 2025, p. 555)

  • Diastolic function and filling pressure: normal, grade 1, grade 2 or grade 3.
  • If you cannot assign a grade, state whether filling pressure is normal or elevated. Report an isolated LVEDP increase separately.
  • Required values: E, A, E/A, e′, average E/e′, TR velocity.
  • The parameters behind your conclusion, for example LARS, pulmonary vein S/D, IVRT, Ar−A.

Age-specific e′ cut-offs (ASE 2025, Table 6, p. 553)

You can use Table 6 instead of the fixed e′ cut-offs. Note the inequality sign: Table 6 uses "<", the figures use "≤".

Ageseptal e′lateral e′average e′
20-39 years< 7< 10< 9
40-65 years< 6< 8< 7
> 65 years< 6< 7< 6.5
Table 5. Reduced e′ by age (cm/s)

ASE 2025 gives no cut-offs for people under 20.

LA reservoir strain (LARS)

LARS ≤ 18% supports elevated filling pressure (ASE 2025, Figs 2 and 3). Values of 19-24% are low-normal. With normal LVEF the parameter is specific but not sensitive: a value above the cut-off does not exclude elevated LAP.

ASE 2025 lists situations where LARS should not be used to estimate filling pressure:

  • atrial fibrillation (the AF algorithm in Fig. 8 is the exception: when 2 of 4 first-step criteria are met, LARS < 18% is one of three second-step criteria),
  • significant mitral regurgitation,
  • heart transplant,
  • normal LVEF with GLS > 18%,
  • LA stunning.

LARS is not mandatory. In Figure 3 it is one of three equal additional variables, alongside pulmonary vein S/D and LAVi.

Special populations

Atrial fibrillation (ASE 2025, Fig. 8, p. 563)

Use average values from several cardiac cycles that reflect the average heart rate. The algorithm has moderate accuracy.

StepCriteriaResult
1E ≥ 100 cm/s; septal E/e′ > 11; TR > 2.8 m/s or PASP > 35 mmHg; DT ≤ 160 ms0-1: normal LAP; ≥ 3: elevated LAP; 2: go to step 2
2LARS < 18%; pulmonary vein S/D < 1; BMI > 300: normal; 1 or missing data: indeterminate; 2-3: elevated

Moderate or severe MAC (ASE 2025, Fig. 4)

Here ASE 2025 relies on E/A and IVRT.

CriterionResult
E/A < 0.8normal LAP
E/A > 1.8elevated LAP
E/A 0.8-1.8 and IVRT ≥ 80 msnormal LAP
E/A 0.8-1.8 and IVRT < 80 mselevated LAP

Pulmonary hypertension (ASE 2025, Fig. 6)

Prefer lateral E/e′, because septal motion is often abnormal.

CriterionResult
E/A ≤ 0.8 and E ≤ 50 cm/snormal LAP
E/A ≥ 2 and reduced e′elevated LAP
all others: LARS > 18% / ≤ 18%normal / elevated LAP
no LARS: lateral E/e′ < 8 / 8-13 / > 13normal / indeterminate / elevated LAP

Heart transplant (ASE 2025, Fig. 5)

The result refers to LAP below 15 mmHg or at least 15 mmHg. E/SR_IVR is the ratio of mitral E velocity to LV strain rate during isovolumic relaxation (SR_IVR, from three apical views).

CriterionResult
average E/e′ < 7LAP < 15 mmHg
average E/e′ > 14LAP ≥ 15 mmHg
average E/e′ 7-14: E/SR_IVR ≤ 200 cm / > 200 cmLAP < 15 / ≥ 15 mmHg
E/SR_IVR not feasible: TR ≤ 2.8 m/s / > 2.8 m/sLAP < 15 / ≥ 15 mmHg
no TRindeterminate

Other conditions (ASE 2025, Table 7 and Fig. 7)

For these groups ASE 2025 lists parameters in the text and a table, without a separate flowchart. The calculator shows them as a checklist, not as an algorithm.

ConditionParameters suggesting elevated filling pressure
mitral stenosisIVRT < 60 ms; A > 1.5 m/s; IVRT/T(E−e′) < 4.2
mitral regurgitationIVRT < 60 ms; Ar−A ≥ 30 ms; IVRT/T(E−e′) < 5.6; E/e′ > 14 only with reduced LVEF
hypertrophic cardiomyopathyaverage E/e′ > 14; Ar−A ≥ 30 ms; TR > 2.8 m/s; LAVi > 34 mL/m²
restrictive cardiomyopathy / amyloidosisaverage E/e′ > 14; DT < 140 ms (text: < 150 ms); E/A > 2.5; IVRT < 50 ms; e′ 3-4 cm/s; "5-5-5" pattern: s′, e′ and a′ < 5 cm/s
LVADE/A > 2; RAP > 10 mmHg; PASP > 40 mmHg; average E/e′ > 14 or septal ≥ 15; LAVi > 33 mL/m²
LBBB, RV pacing, CRTseptal and average E/e′ less reliable; lateral E/e′ may still be valid (text, p. 561)
sinus tachycardiaIVRT ≤ 70 ms; pulmonary vein systolic filling fraction ≤ 40%; average E/e′ > 14
constrictive pericarditis vs restriction (Fig. 7)with E/A > 0.8, dilated IVC and respiratory septal shift: medial e′ > 8 cm/s constriction, 6-8 cm/s mixed constriction and restriction, < 6 cm/s restriction; annulus reversus; expiratory diastolic hepatic vein flow reversal (reversal/forward velocity ratio) ≥ 0.8: definite constriction

Diastolic exercise echocardiography (ASE 2025, pp. 555-556)

Indications: symptoms with grade 1 diastolic dysfunction, or symptoms with indeterminate diastolic function or filling pressure at rest.

ResultCriteria
positiveaverage E/e′ ≥ 14 (or septal ≥ 15) and TR > 3.2 m/s (Key Point 3: ≥ 3.2 m/s)
negativeaverage (or septal) E/e′ < 10 and TR < 2.8 m/s
HFpEF likelyE/e′ > 14 with TR > 2.8 but < 3.2 m/s

An isolated rise in TR velocity without a rise in E/e′ does not support HFpEF. ASE 2025 strongly discourages dobutamine stress testing.

HFpEF according to the 2026 ESC guidelines

New definitions

  • HFrEF: LVEF < 50%.
  • The HFmrEF category no longer exists.
  • HFpEF: LVEF ≥ 50% in a patient whose LVEF has never been < 50%.
  • "Decompensated heart failure" replaces "acute heart failure".
  • Improved LVEF means an absolute increase of ≥ 10 percentage points to > 40%. These patients stay in the HFrEF with improved LVEF category and do not move to HFpEF, because HFpEF requires an LVEF that has never been < 50%.

Diagnostic criteria (ESC 2026, section 5.2.2, p. 25)

All three must be present:

  1. current or prior symptoms and/or signs of heart failure,
  2. LVEF ≥ 50% (never previously < 50%),
  3. objective structural or functional abnormalities consistent with diastolic dysfunction or elevated filling pressure (Table 10), supported by elevated natriuretic peptides.

The work-up starts with pre-test probability. ESC 2026 (Fig. 6) lists these risk factors: advanced age, female sex, atrial fibrillation, ischaemic heart disease, obesity, type 2 diabetes, hypertension, sedentary lifestyle, sleep apnoea, chronic kidney disease, anaemia, pulmonary disease, valvular heart disease, inflammatory/infiltrative disease and other causes.

Natriuretic peptide cut-offs (ESC 2026, Fig. 4)

AgeNT-proBNP: heart failure likelyBNP
< 50 years≥ 125 pg/mL≥ 35 pg/mL (no age adjustment)
50-74 years≥ 250 pg/mL≥ 35 pg/mL
≥ 75 years≥ 500 pg/mL≥ 35 pg/mL

ESC 2026 gives no separate cut-off for AF. Obesity lowers peptide levels, but the guidelines give no numerical correction. Table 9 lists causes of higher and lower concentrations. With NT-proBNP > 2000 pg/mL, echocardiography and specialist review should preferably take place within 2 weeks.

Echocardiographic criteria (ESC 2026, Table 10, p. 25)

ParameterCut-off
LVMI or RWTLVMI ≥ 95 g/m² in women, ≥ 115 g/m² in men, or RWT > 0.42
LAVi> 34 mL/m² in sinus rhythm, > 40 mL/m² in AF
E/e′ at rest> 9 (E/e′ ≥ 15 more specific, less sensitive)
PASP or TRPASP > 35 mmHg or TR > 2.8 m/s

ESC 2026 states that likelihood rises with the number of abnormal parameters but sets no required number. The calculator therefore shows a count of criteria met instead of a yes/no "diagnosed" label.

Mind the different cut-offs: E/e′ > 9 in ESC Table 10 is not the average E/e′ ≥ 14 of ASE 2025 Fig. 3. The two documents answer different questions.

Scores

ESC 2026 recommends no score. The guidelines only cite H2FPEF and HFA-PEFF and advise cautious interpretation, mainly to raise suspicion of HFpEF. The calculator offers H2FPEF as an optional module with this caveat.

H2FPEF score (ASE 2025, p. 565)

ComponentPoints
BMI > 30 kg/m²2
≥ 2 antihypertensive drugs1
paroxysmal or persistent AF3
PASP > 35 mmHg1
age > 60 years1
septal E/e′ > 91

Interpretation per ASE 2025 (p. 565): 0-2 points low, 2-5 intermediate, > 5 high probability of HFpEF (original Reddy et al. bands: 0-1, 2-5, ≥ 6).

The ASE 2025 pathway (Fig. 9, p. 564)

History and natriuretic peptides first, then a full echocardiogram. Exclude significant mitral stenosis, primary mitral regurgitation, aortic stenosis and regurgitation, primary tricuspid regurgitation, significant coronary artery disease, non-cardiac pulmonary hypertension, amyloidosis, hypertrophic cardiomyopathy and constriction. Then assess LAP with Fig. 3. Elevated LAP in the right clinical context confirms HFpEF. Dyspnoea with normal LAP is an indication for stress echo or right heart catheterization. A positive result means HFpEF; a negative one points to a non-cardiac cause of dyspnoea.

Invasive gold standard (ESC 2026)

  • PCWP ≥ 15 mmHg at rest or ≥ 25 mmHg during exercise.
  • LVEDP ≥ 16 mmHg at rest.
  • Right heart catheterization in selected patients with an uncertain diagnosis: class IIb, level C.
  • When the diagnosis remains uncertain: CPET, stress echo, invasive assessment.

HFpEF treatment at a glance (ESC 2026)

TreatmentClass/level
SGLT2 inhibitorI/A
MRA (steroidal or non-steroidal, finerenone)I/A
loop diuretic for congestionI/A
ACE-I, ARB or ARNIIIb/C
semaglutide or tirzepatide with LVEF ≥ 45% and BMI ≥ 30 kg/m²IIa/B1
exercise training (personalised; within cardiac rehabilitation I/B1, outside it I/B2)I/B1

ESC 2026 sets the LVEF threshold for semaglutide and tirzepatide at ≥ 45%. It differs from the 50% threshold in the HFpEF definition.

Common measurement pitfalls

Source: ASE 2025, Tables 3-4, section 3 (p. 551) and the algorithm figures.

  • E and A fusion. When E velocity at the onset of the A wave exceeds 20 cm/s, A is overestimated and E/A underestimated. Do not measure DT in that spectrum.
  • TR from a single window. Look for the TR jet from several windows. ASE 2025 encourages agitated saline or an ultrasound enhancing agent (UEA). Avoid the "blooming" artefact, which overestimates velocity.
  • TR without lung context. V3 applies to patients without parenchymal or vascular lung disease. Calculate PASP only when you can estimate RAP.
  • LAVi without method or exclusions. The value depends on the method (biplane disks or area-length). In athletes, anaemia, AF/atrial flutter and mitral valve disease, a large atrium does not have to mean diastolic dysfunction.
  • LARS without regard to vendor software. The value depends on vendor software. Do not use LARS to estimate filling pressure in significant mitral regurgitation, after heart transplant, with normal LVEF and GLS > 18%, or in LA stunning.
  • E/e′ where it is unreliable. This applies to severe MAC, a mitral prosthesis, pericardial disease and regional wall motion abnormalities. In LBBB, RV pacing and CRT, septal and average E/e′ are less reliable; lateral E/e′ may still be valid.
  • E/e′ in the grey zone. Average E/e′ < 8 is usually normal; 8-14 is a grey zone that needs other parameters.
  • Inadequate Valsalva. The strain is adequate when E falls by > 10%. The patient needs to hold about 40 mmHg for 10 s.
  • Mixing up inequality signs. Average E/e′ has a cut-off of > 14 in Fig. 2 and ≥ 14 in Fig. 3. e′ uses "≤" in the figures and "<" in Table 6. LARS is ≤ 18% in the figures and < 18% in AF.
  • Pulmonary vein S/D with normal LVEF. The ratio can exceed 0.67 despite elevated LAP, and healthy people can have values ≤ 0.67. It is most reliable in systolic dysfunction.

Frequently asked questions

How do you grade diastolic dysfunction according to ASE 2025?

Grade from the Fig. 3 algorithm in sinus rhythm. Grade 1 means reduced e′, normal E/e′ and PASP, E/A ≤ 0.8 and normal LA pressure. Grade 2 means elevated LAP with E/A < 2, grade 3 elevated LAP with E/A ≥ 2. Fig. 2 answers a separate question: whether diastolic dysfunction is present at all, based on e′ plus average E/e′, LARS, E/A and LAVi.

Does the ASE 2025 algorithm apply to patients with reduced LVEF?

Yes. Fig. 3 applies to patients in sinus rhythm regardless of LVEF. Pulmonary vein S/D is most reliable in systolic dysfunction and can mislead when LVEF is normal.

What if there is no measurable tricuspid regurgitation jet?

Search several windows first; ASE 2025 encourages agitated saline or an ultrasound enhancing agent. If TR remains unmeasurable, one of three primary variables is missing. The algorithm then rests on e′ and E/e′, plus the additional variables (S/D, LARS, LAVi, IVRT) and the supplemental methods when needed. After heart transplant, missing TR with unfeasible E/SR_IVR gives an indeterminate result.

Is LA strain required to assess diastolic function?

No. LARS ≤ 18% is one of three equal additional variables in Fig. 3. The mandatory report values are E, A, E/A, e′, average E/e′ and TR velocity.

How do the 2026 ESC guidelines define HFpEF?

HFpEF means current or prior heart failure symptoms and/or signs with LVEF ≥ 50% (never previously < 50%) and objective evidence of diastolic dysfunction or elevated filling pressure from Table 10, supported by elevated natriuretic peptides. ESC 2026 removed HFmrEF; HFrEF is LVEF < 50%.

What is the NT-proBNP cut-off for HFpEF in the 2026 ESC guidelines?

ESC 2026 uses age-specific cut-offs for heart failure in general, not HFpEF-specific values. Heart failure is likely with NT-proBNP ≥ 125 pg/mL under 50 years, ≥ 250 pg/mL at 50-74 years and ≥ 500 pg/mL from 75 years. The BNP cut-off is ≥ 35 pg/mL without age adjustment. There is no separate cut-off for AF.

Is H2FPEF recommended?

No. ESC 2026 recommends no scoring system and cites H2FPEF and HFA-PEFF only as tools for cautious use, mainly to raise suspicion of HFpEF. In this calculator H2FPEF is optional.

When is diastolic stress echo indicated?

In a symptomatic patient with grade 1, or when diastolic function or filling pressure is indeterminate at rest. A positive test means average E/e′ ≥ 14 (or septal ≥ 15) and TR > 3.2 m/s. ASE 2025 strongly discourages dobutamine stress testing.

Learn diastolic function with us

Our courses are currently taught in Polish. Course 12 of the online series Echo od Podstaw covers LV diastolic function: the ASE 2025 algorithm on real cases, from Doppler measurements to the grade and the HFpEF diagnosis.

For the changes from the ASE/EACVI 2016 algorithm, see our Polish article ASE 2025 vs ASE/EACVI 2016: LV diastolic function. Normal values for other parameters are on our Polish page Echocardiographic normal values.

Sources and disclaimer

  1. Nagueh SF, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis: An Update From the American Society of Echocardiography. J Am Soc Echocardiogr 2025;38(7):537-569. DOI: 10.1016/j.echo.2025.03.011
  2. Køber L, Adamo M (Chairpersons), et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J 2026. DOI: 10.1093/eurheartj/ehag100

Disclaimer. This calculator is an educational tool for physicians. It does not replace clinical judgment or the full guideline text. It applies to adults. Do not use it in children, in normal pregnancy or intraoperatively (outside the scope of ASE 2025). The result depends on measurement quality and on whether the patient fits the scope of the chosen algorithm.

Authors

Radosław Piątkowski, MD, PhD, DSc (dr hab. n. med. i n. o zdr.)

Cardiologist and echocardiographer. Assistant professor at the 1st Department of Cardiology, Medical University of Warsaw. Expert, Echocardiography Association of the Polish Cardiac Society. Co-founder of Akademia Echokardiografii. Author page

Monika Budnik, MD, PhD, DSc (dr hab. n. med. i n. o zdr.)

Cardiologist and echocardiographer. Assistant professor at the 1st Department of Cardiology, Medical University of Warsaw. Expert, Echocardiography Association of the Polish Cardiac Society. Co-founder of Akademia Echokardiografii. Author page

Akademia Echokardiografii